Mozavaptan Hydrochloride
Mozavaptan hydrochloride was approved by Pharmaceuticals and Medical Devices Agency of Japan (PMDA) on July 26, 2006. It was developed and marketed as Physuline® by Otsuka in Japan.
Mozavaptan hydrochloride is a vasopressin receptor antagonist. It is indicated for the treatment of hyponatremia due to excessive fluid retention when restriction of fluid intake is ineffective.
Physuline® is available as film-coated tablet for oral use, containing 30 mg of Mozavaptan hydrochloride. The recommended dose is one tablet (30 mg) once daily after a meal.
General Information
Update Date：2016-03-23
- Drug Name：
- Mozavaptan Hydrochloride
- Research Code：
- OPC-31260; OPC-129
- Trade Name：
- Physuline®
- MOA：
- Vasopressin receptor antagonist
- Indication：
- Hyponatremia
- Status：
- Approved
- Company：
- Otsuka (Originator)
- Sales：
- ATC Code：
- C03XA
Approved Countries or Area
Update Date：2016-03-09
| Approval Date | Approval Type | Trade Name | Indication | Dosage Form | Strength | Company | Review Classification |
|---|---|---|---|---|---|---|---|
| 2006-07-26 | Marketing approval | Physuline | Hyponatremia | Tablet, Film coated | 30 mg Mozavaptan hydrochloride | Otsuka |
Chemical Structure
Update Date：2015-08-27
|
Molecular Weight | 464 | ||||||||||||
| Formula | C27H29N3O2 • HCl | |||||||||||||
| CAS No. |
137975-06-5 (Mozavaptan ); 138470-70-9 (Mozavaptan HCl); |
|||||||||||||
| Chemical Name | N-(4-{[(5RS)-5-(dimethylamino)-2,3,4,5-tetrahydro-1H-benzo[b]azepin-1-yl]carbonyl}phenyl)-2-methylbenzamide monohydrochloride | |||||||||||||
| Mozavaptan （Free Acid/Base）Parameters： | ||||||||||||||
|
||||||||||||||
| *：Calculated by ACD/Labs software V11.02. | ||||||||||||||
Synthesis & Impurities
Update Date：2015-10-21
